Long-term Monitoring and Your Care Team
At a Glance
Long-term DADA2 care is individualized and usually involves coordinated rheumatology, hematology, neurology, immunology, and genetics specialists. Regular blood tests, selected brain imaging, family screening, and emotional support help identify complications early and guide treatment.
Managing DADA2 is a marathon, not a sprint. Because this condition can affect multiple organ systems over many years, care transitions from the initial “search for answers” to a phase of careful, individualized surveillance. The goal of this phase is to monitor for new complications, like strokes or bone marrow failure, and to ensure that the inflammation stays managed [1][2].
Building Your Multidisciplinary Care Team
Because DADA2 can wear many “faces,” you or your child need a team of specialists who communicate with each other. A “standard” DADA2 care team typically includes:
- Rheumatology: Often coordinates care, focusing on systemic inflammation and managing TNF inhibitors [1].
- Hematology: Monitors bone marrow health and red/white blood cell counts [3].
- Neurology: Oversees brain health and monitors for any signs of stroke or nerve involvement [4].
- Immunology: Tracks antibody levels and vaccine responses to ensure the immune system is functioning [5].
- Medical Genetics: Provides counseling for family members and helps interpret complex genetic reports [6].
Depending on your specific symptoms, you may also see specialists in Hepatology (liver), Gastroenterology (gut), or Dermatology (skin) [7].
The Long-Term Surveillance Schedule
There is no single monitoring schedule that applies to all patients. Your doctor will tailor your schedule to your specific age, phenotype, recent events, and treatments:
Regular Blood Work
- Inflammatory Markers: Testing for CRP (C-reactive protein) and ESR (sedimentation rate) helps your doctor see if your medication is working [2]. However, it is important to know that a “normal” lab result does not 100% rule out a risk of stroke; symptoms always matter more than labs [8].
- Complete Blood Count (CBC): To watch for “silent” drops in red cells, white cells, or platelets [3].
- Organ Health: Blood pressure, kidney function, and urinalysis.
- Immunoglobulins: To ensure your antibody levels (IgG, IgA, IgM) and vaccine responses are adequate when relevant [5].
Imaging and Organ Health
- Brain MRI/MRA: Routine surveillance imaging is used by some centers to check for “silent” strokes—small areas of damage that don’t cause immediate symptoms but can add up over time [4][9]. However, its timing is not uniform and is individualized based on local expert practice.
- Liver Assessment: DADA2 can cause liver disease or high blood pressure in the liver’s veins (portal hypertension). Depending on your findings and specialist advice, monitoring may include physical examination, liver chemistries, or imaging like ultrasound [7].
- Growth Monitoring: For children, tracking height and weight is vital, as chronic inflammation can sometimes lead to growth delays [10].
Genetic Counseling and Family Screening
DADA2 is a family-wide diagnosis. Once a person is diagnosed, genetic counseling is recommended for the whole family [6].
- Screening Relatives: Siblings of a person with DADA2 have a 25% chance of also having the condition (if both parents are carriers), even if they have no symptoms yet [1]. Testing at-risk relatives for the known familial variants is crucial [11].
- Individualized Treatment: Importantly, finding that an asymptomatic sibling has the genetic variants for DADA2 does not automatically mean they will be prescribed medication. Treatment decisions for affected relatives require careful clinical, biochemical, and specialist assessment [12][6].
The Psychological Toll and Quality of Life
Living with an ultra-rare disease and a constant schedule of monitoring can be exhausting. Many families and adult patients experience:
- “Scan Anxiety”: The stress that builds up before a scheduled MRI or major lab panel [13].
- Chronic Fatigue: While DADA2 itself can cause fatigue, the mental load of managing a complex medical regimen also contributes [10].
- Treatment Burden: The logistics of regular injections (for TNF inhibitors) or frequent hospital visits can impact school, work, and social life.
- Transition to Adult Care: For pediatric patients, transitioning to adult specialists familiar with DADA2 is a major step. Adult patients also face decisions regarding reproductive counseling, pregnancy medication planning, and the fertility implications of treatments like HSCT.
Working with a therapist or a social worker who specializes in chronic illness can help you navigate the emotional aspects of survivorship [6]. Remember, the goal of all this monitoring is not just to “track a disease,” but to give you the security to live your life with as much normalcy as possible.
Common questions in this guide
Which doctors are usually involved in long-term DADA2 care?
How often should brain MRI be done for DADA2?
What tests are part of routine DADA2 monitoring?
Should family members be tested for DADA2?
What should I do if I develop new symptoms between appointments?
How can families manage the emotional burden of long-term DADA2 care?
How should DADA2 care be planned for adulthood or pregnancy?
One line in your results can change your plan.
Liver findings in DADA2 may determine whether your specialist adds imaging such as ultrasound to monitoring. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Deficiency of adenosine deaminase 2.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement.
Lee PY, Davidson BA, Abraham RS, et al.
JAMA network open 2023; (6(5)):e2315894 doi:10.1001/jamanetworkopen.2023.15894.
PMID: 37256629 - 2
Treatment and Outcome in Deficiency of Adenosine Deaminase 2: A Literature Review.
Zhang B, Xu N, Chen J, et al.
Journal of investigational allergology & clinical immunology 2021; (32(1)):13-22 doi:10.18176/jiaci.0748.
PMID: 34489224 - 3
Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities.
Bulté D, Barzaghi F, Mesa-Nuñez C, et al.
The Journal of allergy and clinical immunology 2025; (155(2)):616-627.e8 doi:10.1016/j.jaci.2024.09.007.
PMID: 39284370 - 4
Decoding neurovascular signatures: advanced imaging insights in DADA2-Related Cerebral Microangiopathy.
Zhou Y, Shen M, Jiang N, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (47(1)):18.
PMID: 41413740 - 5
Deficiency of adenosine deaminase 2 skews adaptive immune repertoires toward specific sets of T- and B-cell receptors.
Schultheiß C, Schmidt-Barbo P, Paschold L, et al.
The Journal of allergy and clinical immunology 2025; (155(5)):1664-1674 doi:10.1016/j.jaci.2025.01.032.
PMID: 39924119 - 6
Integrating genetic counseling in endocrine practice: Prevention, reproductive care, and prenatal diagnosis.
Girerd B, Peduto C, Rothenbuhler A, et al.
Annales d'endocrinologie 2026; (87(3)):102518 doi:10.1016/j.ando.2026.102518.
PMID: 41864331 - 7
Hepatic Manifestations and Response to Treatment in Deficiency of Adenosine Deaminase 2.
Shaik MR, Alao H, Shaik NA, et al.
Liver international : official journal of the International Association for the Study of the Liver 2026; (46(6)):e70660 doi:10.1111/liv.70660.
PMID: 42083127 - 8
Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2).
Clarke K, Campbell C, Omoyinmi E, et al.
Pediatric rheumatology online journal 2019; (17(1)):39 doi:10.1186/s12969-019-0334-5.
PMID: 31291964 - 9
Deficiency of adenosine deaminase 2; special focus on central nervous system imaging.
Bulut E, Erden A, Karadag O, et al.
Journal of neuroradiology = Journal de neuroradiologie 2019; (46(3)):193-198 doi:10.1016/j.neurad.2018.05.002.
PMID: 29913178 - 10
Pediatric-Onset Polyarteritis Nodosa and Deficiency of Adenosine Deaminase 2: Clinical Overlap and Divergence.
Atamyildiz Uçar S, Tunce E, Türkmen Ş, et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2025; (31(8)):299-305 doi:10.1097/RHU.0000000000002270.
PMID: 40815801 - 11
A Case Report: Two Young Children with Long QT Syndrome Type-2 Diagnosed by Presymptomatic Genetic Testing.
Matsushita Y, Nagata H, Ogawa M, et al.
Journal of pediatric genetics 2022; (11(4)):313-316 doi:10.1055/s-0040-1719054.
PMID: 36267859 - 12
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.
Frey MK, Ahsan MD, Bergeron H, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(35)):4129-4143 doi:10.1200/JCO.22.00303.
PMID: 35960887 - 13
Approaches to Genetic Screening in Cardiomyopathies: Practical Guidance for Clinicians.
Kontorovich AR
JACC. Heart failure 2023; (11(2)):133-142 doi:10.1016/j.jchf.2022.11.025.
PMID: 36754525
This page is for informational purposes only and does not constitute medical advice about DADA2. Your multidisciplinary care team should tailor surveillance, family testing, and treatment decisions to your or your child’s needs.